Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
177Lu-P17-087
- Development stage
- Phase 1
- Lead developer
- Peking Union Medical College Hospital
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
177Lu-P17-087 is a novel radiopharmaceutical designed for targeted radioligand therapy (RLT) in metastatic castration-resistant prostate cancer (mCRPC). It consists of the beta-emitting radioisotope lutetium-177 conjugated to a ligand that targets the prostate-specific membrane antigen (PSMA), which is highly expressed on prostate cancer cells. By binding to PSMA, 177Lu-P17-087 delivers localized ionizing radiation directly to tumor sites, aiming to damage and kill cancer cells while sparing surrounding healthy tissue. Early clinical studies have demonstrated excellent PSMA-targeting dose delivery, favorable pharmacokinetics with rapid tumor uptake and clearance, and promising reductions in PSA levels among treated patients. The drug is being developed by Five Eleven Pharma in collaboration with Peking Union Medical College Hospital[1][3][8][10].
- Other names
- [177Lu]Lu-P17-087
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on 177Lu-P17-087.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 177Lu-P17-087.